Sign in Subscribe

Latest

Zilganersen ASO Reverses Functional Decline in Alexander Disease Ahead of 2026 PDUFA

Zilganersen, Alexander Disease, Rare Disease, Neurology, FDA PDUFA

Zilganersen ASO Reverses Functional Decline in Alexander Disease Ahead of 2026 PDUFA

First-in-class antisense oligonucleotide demonstrates age-dependent functional improvements and robust biomarker reduction, overcoming the absolute limitations of palliative standard of care. See Disclaimer below * Alexander disease is an ultra-rare leukodystrophy that has, until now, sat entirely outside the reach of disease-modifying therapy. Global prevalence sits between 1 in 1,000,000

By Jitesh Rana, MD, Dr. Gina Ayala, Beloo Mirakhur, MD PhD, Mo Elsafy, MD MSc
Dual-Targeting Mechanism Achieves Lesion Suppression but Severe Hepatotoxicity Precludes Frontline Utility

Neurology

Dual-Targeting Mechanism Achieves Lesion Suppression but Severe Hepatotoxicity Precludes Frontline Utility

Phase 3 data demonstrates fenebrutinib effectively halts acute peripheral inflammation, but the therapeutic window is aggressively narrowed by drug-induced liver injury risks and necessary hepatic monitoring protocols. See Disclaimer below * The global Relapsing Multiple Sclerosis (RMS) market operates as a massive commercial theater, encompassing approximately 800,000 prevalent patients in

By Jitesh Rana, MD, Mo Elsafy, MD MSc
SKY-0515 Demonstrates First-in-Class Restorative Potential in Huntington's Disease, Establishing New Standard of Care Trajectory

Neurology

SKY-0515 Demonstrates First-in-Class Restorative Potential in Huntington's Disease, Establishing New Standard of Care Trajectory

Phase 1 interim data suggests a restorative signal (+0.64 cUHDRS) distinct from competitor stabilization, driven by deep target engagement and somatic expansion inhibition. See Disclaimer below * Unmet Medical Need Huntington’s Disease (HD) remains a fatal, autosomally dominant neurodegenerative disorder with no approved disease-modifying therapies (DMTs). The current prevalence

By Jitesh Rana, MD
ACI-7104.056 Parkinson’s "Vaccine": Interim VacSYn Data Challenges the "Symptomatic Only" Treatment Paradigm

Neurology

ACI-7104.056 Parkinson’s "Vaccine": Interim VacSYn Data Challenges the "Symptomatic Only" Treatment Paradigm

AC Immune’s Phase 2 interim analysis delivers a rare trifecta in neurodegeneration: 100% target engagement, biomarker stabilization, and clinical efficacy signals. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * In a therapeutic

By Jitesh Rana, MD
TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Neurology

TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Kallyope's first-in-class oral antagonist meets co-primary endpoints, offering a distinct non-CGRP mechanism for refractory patients. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Impact Analysis The landscape of acute migraine

By Jitesh Rana, MD